HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Clinical trial NCT05029973 · UNKNOWN
Trial details
- NCT number
- NCT05029973
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-10
- Primary completion
- 2022-01-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.